Participating Faculty

The American Journal of Managed Care

This supplement to is based on presentations by BruceR. Bacon, MD, and John G. McHutchison, MD, and contains information on the current treatmentof hepatitis C, including compliance issues, impact on special populations, and outlookfor long-term health. Paul Courter, a freelance medical writer and editor, assisted in the writingand editing of this supplement.

Faculty

Bruce R. Bacon, MD

James F. King, MD Endowed Chair in Gastroenterology

Director of the Division of Gastroenterology and Hepatology

Professor of Internal Medicine

Saint Louis University

School of Medicine

Saint Louis, Missouri

John G. McHutchison, MD

Director of Gastroenterology/Hepatology Research

Duke Clinical Research Institute

Professor of Medicine

Duke University Medical Center

Durham, North Carolina

Faculty Disclosure

In accordance with the ACCME and the ACPE, participants for this activity have completed conflict-of-intereststatements.

In compliance with the Health Insurance Portability and Accountability Act standards, no presentations inthis CME/CE activity shall disclose the names or other identifiers of patients referenced without a signedwaiver from the identified patient.

The American Journal of Managed Care

It is the policy of to have all faculty who participate in programssponsored by corporate organizations disclose any real or apparent conflicts of interest.

• Bruce R. Bacon, MDConsultant To:ColeyISISSchering-PloughSerono InternationalAdvisor To:Bayer DiagnosticGenetrol BiotherapeuticsGlaxoSmithKlineMetaphoreResearch Support From:Bristol-Myers SquibbGilead SciencesGlaxoSmithKlineISISRocheSchering-PloughSpeakers'Bureau For:Axcan PharmaGilead SciencesSchering-Plough
• John G. McHutchison, MDGrant/Research Support From:Akros PharmaAmgenBayerBio-MedicinesBristol-Myers SquibbColeyFujisawaGilead SciencesGlaxoSmithKlineHuman Genome SciencesIDUNISISOrtho Diagnostic SystemsPrometheus LaboratoriesRibozymeRocheSchering-PloughSciCloneTriangeVertexConsultant/Advisor To/Speaker For:AmgenAnadysAus Bio PTLCentocorGlaxoSmithKlineIdenixInterMuneISISNational Genetics InstituteNovartisNucleonicsPfizerPODPrometheus LaboratoriesRibozymeRigelSchering-PloughSIRNA TherapeuticsUnited TherapeuticsXTL

Investigational and/or Off-label Use of Commercial Products and Devices

The University of Cincinnati College of Medicine requires all faculty to disclose any discussion ofinvestigational and/or off-label use of a pharmaceutical product or device within their presentation.Participants should note that the use of products outside US Food and Drug Administration-approvedlabeling should be considered experimental and are advised to consult current prescribing informationfor approved indications.

The faculty claim not to discuss any investigational and/or off-label use of a pharmaceutical productor device.

The American Journal of Managed Care,

Signed disclosures are on file at the offices of Jamesburg,New Jersey.

Download PDF: Participating Faculty